Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMFMWYC)

• Drug Name: Resatorvid Drug Info
• Synonyms: Resatorvid; TAK-242; 243984-11-4; UNII-H2MZ648C31; CHEMBL225157; H2MZ648C31; TAK242; Resatorvid [INN]; TAK-242 (Resatorvid); C15H17ClFNO4S; SCHEMBL872197; GTPL9036; MolPort-035-773-739; BDBM50155929; ZINC13982410; 4003AH; AKOS027250774; CS-0408; KB-80786; AN-16512; HY-11109; A3850; W-5468; P111021; ethyl (6R)-6-[(2-chloro-4-fluorophenyl)sulfamoyl]cyclohexene-1-carboxylate; ethyl (6r)-6-[n-(2-chloro-4-fluorophenyl)sulfamoyl]cyclohex-1-ene-1-carboxylate; ethyl (6R)-6-[(2-chloro-4-fluoro-phenyl)sulfamoyl]cyclohexene-1-carboxylate

Indication

Disease Entry	ICD 11	Status	REF
Sepsis	1G40-1G41	Phase 3	[1]

• Cross-matching ID:
  PubChem CID: 11703255
  ChEBI ID: CHEMBL225157
  CAS Number: CAS 243984-11-4
  TTD Drug ID: DMFMWYC

Molecule-Related Drug Atlas

Drug(s) Targeting Toll-like receptor 4 (TLR4)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
MPL-containing Pollinex allergy desensitization vaccine	DMXSDJU	Allergy	4A80-4A85	Preregistration	[4]
Cadi-05	DMPTCYB	Prostate cancer	2C82.0	Phase 3	[5]
ERITORAN	DMKQZ0L	Sepsis	1G40-1G41	Phase 3	[6]
G100	DMKHNXA	Non-hodgkin lymphoma	2B33.5	Phase 2	[7]
OM-174	DM2THBX	Solid tumour/cancer	2A00-2F9Z	Phase 1	[8]
NI-0101	DM31FOP	Autoimmune diabetes	5A10	Phase 1	[9]
GSK1795091	DMC6QE4	Solid tumour/cancer	2A00-2F9Z	Phase 1	[7]
CRX-675	DMHDSYF	Hepatitis virus infection	1E50-1E51	Phase 1	[9]
CS-4771	DMVDLT4	Sepsis	1G40-1G41	Discontinued in Phase 1	[10]
LZ-8	DM679IY	Autoimmune diabetes	5A10	Terminated	[9]

Drug(s) Affected By Transcription factor p65 (RELA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Cannabidiol	DM0659E	Dravet syndrome	8A61.11	Approved	[11]
Beta-carotene	DM0RXBT	Vitamin deficiency	5B55-5B71	Approved	[12]
Selenium	DM25CGV	N. A.	N. A.	Approved	[13]
Sulindac	DM2QHZU	Acute myelogenous leukaemia	2A41	Approved	[14]
Simvastatin	DM30SGU	Arteriosclerosis	BD40	Approved	[15]
Deoxycholic acid	DM3GYAL	Subcutaneous fat disorder	EF02	Approved	[16]
Quercetin	DM3NC4M	Obesity	5B81	Approved	[17]
Troglitazone	DM3VFPD	Diabetic complication	5A2Y	Approved	[18]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[19]
Glucosamine	DM4ZLFD	Osteoarthritis	FA00-FA05	Approved	[20]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Toll-like receptor 4 (TLR4)	TTISGCA	TLR4_HUMAN	Antagonist	[2]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Transcription factor p65 (RELA)	OTUJP9CN	TF65_HUMAN	Post-Translational Modifications	[3]
Vascular endothelial growth factor A, long form	OTIM9MZ3	VEGFA_HUMAN	Gene/Protein Processing	[3]

References

• [1] ClinicalTrials.gov (NCT00633477) Efficacy and Safety of Resatorvid in Patients With Sepsis-induced Cardiovascular and Respiratory Failure. U.S. National Institutes of Health.
• [2] Clinical pipeline report, company report or official report of Takeda (2009).
• [3] 7?Difluoromethyl?5,4'?dimethoxygenistein exerts anti?angiogenic effects on acute promyelocytic leukemia HL?60 cells by inhibiting the TLR4/NF?B signaling pathway. Mol Med Rep. 2020 May;21(5):2251-2259. doi: 10.3892/mmr.2020.11029. Epub 2020 Mar 18.
• [4] Allergy Therapeutics PLC. News Announcement. Allergy Therapeutics. Clinical Trials. Allergy Therapeutics PLC. 11 October 2006.
• [5] Trial Watch: Experimental Toll-like receptor agonists for cancer therapy. Oncoimmunology. 2012 August 1; 1(5): 699-716.
• [6] Small molecule modulators of toll-like receptors. J Med Chem. 2008 Nov 13;51(21):6621-6.
• [7] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [8] Phase I study of OM-174, a lipid A analogue, with assessment of immunological response, in patients with refractory solid tumors. BMC Cancer. 2013 Apr 2;13:172.
• [9] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1754).
• [10] Eritoran insight for influenza treatment. SciBX 6(19); doi:10.1038/scibx.2013.453. May 16 2013
• [11] Cannabidiol Modulates the Immunophenotype and Inhibits the Activation of the Inflammasome in Human Gingival Mesenchymal Stem Cells. Front Physiol. 2016 Nov 24;7:559. doi: 10.3389/fphys.2016.00559. eCollection 2016.
• [12] -Carotene Induces Apoptosis in Human Esophageal Squamous Cell Carcinoma Cell Lines via the Cav-1/AKT/NF-B Signaling Pathway. J Biochem Mol Toxicol. 2016 Mar;30(3):148-57. doi: 10.1002/jbt.21773. Epub 2016 Jan 6.
• [13] Selenium and vitamin E: cell type- and intervention-specific tissue effects in prostate cancer. J Natl Cancer Inst. 2009 Mar 4;101(5):306-20.
• [14] Differential gene expression of sulindac-treated human breast epithelial cells. Int J Oncol. 2005 Dec;27(6):1727-36.
• [15] Suppression of RAGE as a basis of simvastatin-dependent plaque stabilization in type 2 diabetes. Arterioscler Thromb Vasc Biol. 2006 Dec;26(12):2716-23.
• [16] Prevention of deoxycholate-induced gastric apoptosis by aspirin: roles of NF-kappaB and PKC signaling. J Surg Res. 2008 Mar;145(1):66-73. doi: 10.1016/j.jss.2007.04.039. Epub 2007 Jul 20.
• [17] Comparison of phenotypic and transcriptomic effects of false-positive genotoxins, true genotoxins and non-genotoxins using HepG2 cells. Mutagenesis. 2011 Sep;26(5):593-604.
• [18] Peroxisome proliferator-activated receptor-gamma agonists inhibit respiratory syncytial virus-induced expression of intercellular adhesion molecule-1 in human lung epithelial cells. Immunology. 2007 May;121(1):71-81. doi: 10.1111/j.1365-2567.2006.02539.x.
• [19] Differential modulation of PI3-kinase/Akt pathway during all-trans retinoic acid- and Am80-induced HL-60 cell differentiation revealed by DNA microarray analysis. Biochem Pharmacol. 2004 Dec 1;68(11):2177-86.
• [20] Glucosamine regulation of LPS-mediated inflammation in human bronchial epithelial cells. Eur J Pharmacol. 2010 Jun 10;635(1-3):219-26. doi: 10.1016/j.ejphar.2010.02.044. Epub 2010 Mar 20.